Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in ...

Tesla’s latest annual general meeting gave investors more than just the approval of Elon Musk’s $1 trillion compensation package to think about, according to Morgan Stanley.

Tesla’s (NASDAQ:TSLA) recent annual general meeting gave investors plenty to digest beyond the approval of Elon Musk’s $1 ...

Q3 2025 Earnings Call November 13, 2025 9:00 AM ESTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid ...

In the traditional view, affordances exist as options users perceive and act upon within their environment. However, in the age of genAI, affordances have become relational folds, dynamic exchanges in ...

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

This study offers a valuable advance for neuroscience by extending a visualization tool that enables intuitive assessment of how dendritic and synaptic currents shape the output of neurons. The ...